These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 21372562)

  • 1. Protective effect of the vasopressin agonist terlipressin in a rat model of contrast-induced nephropathy.
    Ari E; Yilmaz Y; Kedrah AE; Alahdab Y; Cakalagaoglu F; Arikan H; Kocak H; Macunluoglu B; Atakan A; Kahveci A; Asicioglu E; Tuglular S; Ozener C
    Am J Nephrol; 2011; 33(3):269-76. PubMed ID: 21372562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Terlipressin in hepatorenal syndrome: Evidence for present indications.
    Rajekar H; Chawla Y
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():109-14. PubMed ID: 21199521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of terlipressin during living donor liver transplantation: Effects on systemic and splanchnic hemodynamics and renal function.
    Mukhtar A; Salah M; Aboulfetouh F; Obayah G; Samy M; Hassanien A; Bahaa M; Abdelaal A; Fathy M; Saeed H; Rady M; Mostafa I; El-Meteini M
    Crit Care Med; 2011 Jun; 39(6):1329-34. PubMed ID: 21336108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Vasopressin and terlipressin in sepsis and systemic inflammatory response syndrome. Effects on microcirculation, oxygen transport, metabolism and organ function].
    Ertmer C; Sielenkämper AW; van Aken H; Bone HG; Westphal M
    Anaesthesist; 2005 Apr; 54(4):346-56. PubMed ID: 15625598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Terlipressin for children with extremely low cardiac output after open heart surgery.
    Matok I; Rubinshtein M; Levy A; Vardi A; Leibovitch L; Mishali D; Barzilay Z; Paret G
    Ann Pharmacother; 2009 Mar; 43(3):423-9. PubMed ID: 19261966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasopressin analogs in portal hypertension: different molecules but similar questions.
    Blei AT
    Hepatology; 1986; 6(1):146-7. PubMed ID: 3510949
    [No Abstract]   [Full Text] [Related]  

  • 7. A long-acting vasopressin analog for septic shock: brilliant idea or dangerous folly?
    Berg RA
    Pediatr Crit Care Med; 2004 Mar; 5(2):188-9. PubMed ID: 15080105
    [No Abstract]   [Full Text] [Related]  

  • 8. Terlipressin, a provasopressin drug exhibits direct vasoconstrictor properties: consequences on heart perfusion and performance.
    Ryckwaert F; Virsolvy A; Fort A; Murat B; Richard S; Guillon G; Colson PH
    Crit Care Med; 2009 Mar; 37(3):876-81. PubMed ID: 19237891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of F-180, a new selective vasoconstrictor peptide, compared with terlipressin and vasopressin on systemic and splanchnic hemodynamics in a rat model of portal hypertension.
    Bernadich C; Bandi JC; Melin P; Bosch J
    Hepatology; 1998 Feb; 27(2):351-6. PubMed ID: 9462630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contrast-induced nephropathy: protective role of fenoldopam.
    Caixeta A; Dogan O; Weisz G
    Clin Exp Pharmacol Physiol; 2012 Jun; 39(6):497-505. PubMed ID: 22642656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contrast-induced nephropathy.
    Marenzi G; Cabiati A; Milazzo V; Rubino M
    Intern Emerg Med; 2012 Oct; 7 Suppl 3():S181-3. PubMed ID: 23073854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome.
    Krag A; Borup T; Møller S; Bendtsen F
    Adv Ther; 2008 Nov; 25(11):1105-40. PubMed ID: 19018483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Terlipressin: vasopressin analog and novel drug for septic shock.
    Pesaturo AB; Jennings HR; Voils SA
    Ann Pharmacother; 2006 Dec; 40(12):2170-7. PubMed ID: 17148649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient with a sudden drop in blood pressure.
    Oliver JA; Landry DW
    Crit Care Med; 2003 Jan; 31(1):326-7. PubMed ID: 12545047
    [No Abstract]   [Full Text] [Related]  

  • 15. Vasopressin and terlipressin: pharmacology and its clinical relevance.
    Kam PC; Williams S; Yoong FF
    Anaesthesia; 2004 Oct; 59(10):993-1001. PubMed ID: 15488059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Terlipressin increased the concentration of L-lactate in the rectal lumen in a patient with septic shock.
    Perner A; Jørgensen VL; Waldau T
    Acta Anaesthesiol Scand; 2004 Sep; 48(8):1054-7. PubMed ID: 15315626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Terlipressin inhibits in vivo aortic iNOS expression induced by lipopolysaccharide in rats with biliary cirrhosis.
    Moreau R; Barrière E; Tazi KA; Lardeux B; Dargère D; Urbanowicz W; Poirel O; Chauvelot-Moachon L; Guimont MC; Bernuau D; Lebrec D
    Hepatology; 2002 Nov; 36(5):1070-8. PubMed ID: 12395316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Terlipressin: a promising vasoactive agent in hemodynamic support of septic shock.
    Morelli A; Ertmer C; Pietropaoli P; Westphal M
    Expert Opin Pharmacother; 2009 Oct; 10(15):2569-75. PubMed ID: 19735216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review article: pharmacological treatment of hepatorenal syndrome.
    Ginès P; Torre A; Terra C; Guevara M
    Aliment Pharmacol Ther; 2004 Sep; 20 Suppl 3():57-62; discussion 63-4. PubMed ID: 15335404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond.
    Moreau R; Lebrec D
    Hepatology; 2006 Mar; 43(3):385-94. PubMed ID: 16496352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.